Pateon Italia S.p.A. (manufacturing of medicinal product, testing at release, stability testing, primary packaging)

The drug is intended for enzyme replacement therapy in patients with mild to moderate alpha-mannosidosis (provided that neurological manifestations of the disease are not yet pronounced).

Dosage form: powder for solution for infusion

ATC: A16AB15